logo

ABOS

Acumen·NASDAQ
--
--(--)
--
--(--)

ABOS fundamentals

Acumen (ABOS) released its earnings on Mar 26, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.4 (YoY +35.48%), beat estimates.
Revenue / YoY
0
--
EPS / YoY
-0.4
+35.48%
Report date
Mar 26, 2026
ABOS Earnings Call Summary for Q4,2025
  • ALTITUDE-AD Progress: Phase II trial enrollment complete, OLE transition smooth with high retention, targeting 2026 readout.
  • EBD Breakthrough: Preclinical data shows 14-40x brain penetration, with multiple viable candidates for mid-2027 IND filing.
  • Funding Strength: $35.75M private placement supports EBD, cash runway extends to early 2027.
  • Safety Profile: Nonhuman primate studies show no significant anemia risk, aligning with JCR's clinical data.
  • Strategic Differentiation: IgG2 subclass of sabirnetug may reduce ARIA-e risk, positioning for Phase III success.

Earnings

EPS
Revenue

Revenue & Expenses

Key Indicators

Acumen (ABOS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Acumen (ABOS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown

Balance Sheet

Acumen (ABOS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown

Cash Flow

Acumen (ABOS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown

Revenue Breakdown

Where does Acumen (ABOS) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:

Dividend

Track Acumen (ABOS) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield